Doctronic CAIHL draft report

Doctronic: CAIHL reassessment

September 8, 2026. Published AI-assisted draft.

This profile covers Doctronic consumer consultation with optional clinical escalation. Patients choose the initial question and whether to seek further care. Commercial incentives require scrutiny, but this pass did not establish that users are forced toward paid care. Prescription-renewal deployments require separate assessment.

Scope and agency posture

Doctronic anonymous AI consultation, distinct from identified member records, paid clinician visits, and prescription-renewal decisions. Consumer-directed entry into a vendor-operated care platform.

Posture: Potentially agency-expanding, with vendor-funnel and framing caveats.

Axis: 75/100, retained provisionally. No numerical recalibration was performed.

Sources and documented findings

• The homepage offers free anonymous consultation, paid doctor visits, and explicitly says users can take the result to their own doctor. Its treatment-plan pitch coexists with a footer denying medical advice by the AI.

• The privacy notice documents human physician review on request, optional record imports, correction/export rights, and stopping provider-initiated retrieval.

• The notice's June 18 update discloses identifiable email engagement tracking with 90-day retention. It separates anonymous use from member medical records, some retained at least seven years.

Patient authority

Inference from the documented workflow: Patients can choose questions and an outside clinician. The evidence supports an offered paid pathway, not a demonstrated forced funnel. Member treatment and renewal workflows give the operator additional responsibilities and access.

Critical capacity

Editorial assessment: Portable assessments and human review can support comparison and challenge. The source does not demonstrate that generated evidence is accurate or that a human reviewer evaluates independently.

Informed control

Editorial assessment: The policy offers unusually concrete rights, but headline clinical language and the AI disclaimer send different signals about reliance. Anonymous and identified use must not share one blanket privacy claim.

Assessment and limits

Keep the qualified agency finding while separating deployment modes. The baseline inference that the model routes users commercially exceeds the observed evidence. Tracking corrections are material factual updates.

Confidence: Medium for published choices and rights.

Remaining uncertainty: Actual anonymous unlinkability, paid-escalation presentation, independent review mechanics, citation reliability, and renewal oversight.

Published documentation is evidence of stated conditions, not proof of actual implementation. Unknowns did not receive automatic negative points. Funding, sponsorship, and public code do not determine agency by themselves.

Review provenance

• Reviewer/model: OpenAI Codex / GPT-6.
• Method: Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
• Human review: Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
• Earlier review: 2026-06-10. Historical assessment. Earlier claims are not automatically reverified by this publication.